JPRN-UMIN000014578招募中3 期
Randomized phase III study for unresectable WHO Grade II diffuse astrocytoma with radiotherapy alone or chemoradiotherapy with temozolomide(JCOG1303, DARTS (Phase-III)) - (JCOG1303, DARTS (Phase-III))
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 260 人开始时间: 2014年7月17日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 69years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy, except for carcinoma in situ or mucosal tumors curatively treated with local therapy 2) Active infection requiring systemic therapy 3) Active infectious meningitis 4) Body temperature >= 38 degrees Celsius at registration 5) Women during pregnancy, possible pregnancy, within 28 days after delivery, or breast-feeding 6) Psychosis or with psychotic symptom 7) Continuous systemic use of steroid or immunosuppressant for disease except for brain tumor 8) Uncontrolled diabetes mellitus or routine administration of insulin 9) Unstable angina within 3 weeks, or with a history of myocardial infarction within 6 months 10) Interstitial pneumonia, pulmonary fibrosis, or severe lung emphysema 11) Gadolinium allergy 12) Positive HIV antibody 13) Potitive HBs antigen
研究者
相似试验
进行中（未招募）
1 期
Randomisierte Phase III Studie für Patienten mit Multiplem Myelom zur Untersuchung zweier Therapieschemata einer Bortezomib-basierten Induktionsthearpie und einer Lenalidomid-Konsolidierungstherapie gefolgt von einer Erhaltungstherapie mit Lenalidomidmultiple myeloma (symptomatic, newly diagnosed)EUCTR2010-019173-16-DEniversity Hospital Heidelberg604
已完成
3 期
Is regional anaesthesia associated with postoperative cognitive deficit? A prospective randomised controlled trial.Mental Health - Studies of normal psychology, cognitive function and behaviourPost Operative Cognitive Dysfunction (POCD)Anaesthesiology - Other anaesthesiologyACTRN12605000150640Dr. Brendan Silbert200
已完成
不适用
A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumabCancerLeukaemiaISRCTN25180151Rigshospitalet (Denmark)300
进行中（未招募）
1 期
A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumabEUCTR2005-000309-75-CZHOVON CLL Group300
尚未招募
3 期
Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancercancerNL-OMON53938niversiteit voor Wetenschap en Technologie155